fashion -WSS

fashion

author：focus 2025-09-03 11:59:36 - browse：6

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： First Opinion Podcast: Long Covid needs a new approach

hotspot

leisure time

WSS

Naloxone nonprofit donates 200,000 doses after FDA approval

Wegovy trial has doctors encouraged over new possibilities

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Researchers explore possible ties between long Covid, menopause

Why failed clinical trials don’t always spell doom for a new drug

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Guidelines to prevent youth baseball injuries need more muscle

Anavex keeps shifting the goalposts in its clinical trials

DIEP, the 'gold standard' of breast reconstruction, is under threat

UnitedHealth’s board chair also owns a personal investment firm

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Will Ozempic

Heart attack and stroke risk calculators need revising

Wegovy trial has doctors encouraged over new possibilities

explore

Eli Lilly expects to double planned employment in Boston center

STAT Summit: GSK CEO on pharma giant's new direction

The best solution to the drug shortages problem

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Drastic changes should bring profitability, startup health insurers say

STAT Summit: Biotech founders on deal

Wikipedia

hotspot

leisure time

leisure time